← All research updates

Testing silevertinib added to temozolomide for newly diagnosed glioblastoma

Original title: Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

How far along is this research?

This is a trial that is enrolling or has been updated. It is not a finding yet.

This is a middle stage trial, so the drug is still being tested in people.

Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.

The trial team last updated this record on . Always check the trial page for the latest.

The short version

This trial is testing whether adding a drug called silevertinib to temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary works better than temozolomide alone.

Who this trial is for. This trial is for people with newly diagnosed glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary, a type of brain tumor. It is for people whose tumor has an unmethylated MGMT promoter methylation: MGMT is a gene whose protein repairs damage to a tumor's DNA. Methylation turns it down. Your report says how much, and your team uses that when they choose chemotherapy. The line between high and low is not settled. See the glossary marker and an EGFRvIII marker. It tests silevertinib combined with temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary after surgery and radiation, compared with temozolomide alone.

Where it stands. This trial has not reported results. The team is still working out how much of the study drugs to give. They are watching for side effects. They are also measuring whether the combination helps people live longer without the tumor getting worse than temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary alone does. The answers are not in yet.

What this means, and what it doesn't

What it could mean: If your tumor has these markers, this is one option you could ask your care team about. Your team can tell you if it fits your situation.

What it doesn't mean: This does not mean silevertinib is a proven treatment. A trial is a test. Researchers do not yet know if it helps. Joining a trial is not a guarantee that it will help you. It is not a promise of a cure.

Source: ClinicalTrials.gov, August 6, 2026 · Read the original

This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.

Report a problem with this summary